同源与异源加强针对灭活SARS-CoV-2疫苗的有效性:一项大规模前瞻性队列研究
在智利全国前瞻性观察队列中,评估完成CoronaVac基础免疫者接种CoronaVac同源加强、AZD1222或BNT162b2异源加强相比未接种者的疫苗有效性。异源加强针对有症状COVID-19、住院、ICU入住和死亡的有效性均高于同源加强,作者认为结果为混合接种策略提供了额外支持。
要点
- 完成CoronaVac基础免疫后,BNT162b2加强针对有症状COVID-19有效性96·5%,AZD1222为93·2%,CoronaVac同源加强为78·8%。
- 针对住院、ICU入住和死亡,异源加强针有效性均高于CoronaVac同源加强。
- 作者认为同源或异源加强针均提供高水平保护,异源加强针在所有结局上有效性更高。
核心结论
- 作者认为,对完成CoronaVac基础免疫者,同源或异源加强针均对有症状COVID-19、重症和死亡提供高水平保护。
- 异源加强针在所有结局上的疫苗有效性均高于同源加强,为混合接种策略提供了额外支持。
研究设计与样本
- 前瞻性、观察性、全国水平队列研究,使用个体水平数据,纳入智利Fondo Nacional de Salud保险体系内年龄≥16岁人群。
- 评估完成CoronaVac两剂基础免疫后接种CoronaVac、AZD1222或BNT162b2加强针者,与未接种者比较。
- 纳入2021年2月2日至预设研究终点2021年11月10日接种疫苗者,排除2021年2月2日或之前可能或确诊SARS-CoV-2感染者及此前已接种至少一剂任何COVID-19疫苗者。
- 共11 174 257人符合条件,其中4 127 546人完成CoronaVac两剂基础免疫并在研究期间接种加强针。
- 采用逆概率加权和分层生存回归模型估计风险比,考虑时间变化的接种状态并校正人口学、社会经济和临床混杂因素。
主要发现
- 4 127 546名完成CoronaVac基础免疫并接种加强针者中,1 921 340人(46·5%)接种AZD1222加强针,2 019 260人(48·9%)接种BNT162b2加强针,186 946人(4·5%)接种CoronaVac同源加强针。
- 预防有症状COVID-19的校正疫苗有效性:CoronaVac三剂程序78·8%(95%CI 76·8-80·6),BNT162b2加强针96·5%(96·2-96·7),AZD1222加强针93·2%(92·9-93·6)。
- 预防COVID-19相关住院的校正疫苗有效性:CoronaVac同源加强86·3%(83·7-88·5),BNT162b2加强96·1%(95·3-96·9),AZD1222加强97·7%(97·3-98·0)。
- 预防ICU入住的校正疫苗有效性:CoronaVac同源加强92·2%(88·7-94·6),BNT162b2加强96·2%(94·6-97·3),AZD1222加强98·9%(98·5-99·2)。
- 预防死亡的校正疫苗有效性:CoronaVac同源加强86·7%(80·5-91·0),BNT162b2加强96·8%(93·9-98·3),AZD1222加强98·1%(97·3-98·6)。
关键数值与推荐
- 有症状COVID-19的校正疫苗有效性:CoronaVac同源加强78·8%(95%CI 76·8-80·6),BNT162b2加强96·5%(96·2-96·7),AZD1222加强93·2%(92·9-93·6)。
- 住院的校正疫苗有效性:CoronaVac同源加强86·3%(83·7-88·5),BNT162b2加强96·1%(95·3-96·9),AZD1222加强97·7%(97·3-98·0)。
- ICU入住的校正疫苗有效性:CoronaVac同源加强92·2%(88·7-94·6),BNT162b2加强96·2%(94·6-97·3),AZD1222加强98·9%(98·5-99·2)。
- 死亡的校正疫苗有效性:CoronaVac同源加强86·7%(80·5-91·0),BNT162b2加强96·8%(93·9-98·3),AZD1222加强98·1%(97·3-98·6)。
临床怎么用
- 作者认为,对完成CoronaVac基础免疫者,同源或异源加强针均提供高水平保护,异源加强针有效性更高,为混合接种策略提供了额外支持。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several countries have authorised or begun using a booster vaccine dose against COVID-19. Policy makers urgently need evidence of the effectiveness of additional vaccine doses and its clinical spectrum for individuals with complete primary immunisation schedules, particularly in countries where the primary schedule used inactivated SARS-CoV-2 vaccines. METHODS: Using individual-level data, we evaluated a prospective, observational, national-level cohort of individuals (aged ≥16 years) affiliated with the Fondo Nacional de Salud insurance programme in Chile, to assess the effectiveness of CoronaVac (Sinovac Biotech), AZD1222 (Oxford-AstraZeneca), or BNT162b2 (Pfizer-BioNTech) vaccine boosters in individuals who had completed a primary immunisation schedule with CoronaVac, compared with unvaccinated individuals. Individuals administered vaccines from Feb 2, 2021, to the prespecified study end date of Nov 10, 2021, were evaluated; we excluded individuals with a probable or confirmed SARS-CoV-2 infection (RT-PCR or antigen test) on or before Feb 2, 2021, and individuals who had received at least one dose of any COVID-19 vaccine before Feb 2, 2021. We estimated the vaccine effectiveness of booster doses against laboratory-confirmed symptomatic COVID-19 (symptomatic COVID-19) cases and COVID-19 outcomes (hospitalisation, admission to the intensive care unit [ICU], and death We used inverse probability-weighted and stratified survival regression models to estimate hazard ratios, accounting for time-varying vaccination status and adjusting for relevant demographic, socioeconomic, and clinical confounders. We estimated the change in hazard from unvaccinated status to vaccinated status associated with the primary immunisation series and a booster vaccine. FINDINGS: 11 174 257 individuals were eligible for this study, among whom 4 127 546 completed a primary immunisation schedule (two doses) with CoronaVac and received a booster dose during the study period. 1 921 340 (46·5%) participants received an AZD1222 booster, 2 019 260 (48·9%) received a BNT162b2 booster, and 186 946 (4·5%) received a homologous booster with CoronaVac. We calculated an adjusted vaccine effectiveness (weighted stratified Cox model) in preventing symptomatic COVID-19 of 78·8% (95% CI 76·8-80·6) for a three-dose schedule with CoronaVac, 96·5% (96·2-96·7) for a BNT162b2 booster, and 93·2% (92·9-93·6) for an AZD1222 booster. The adjusted vaccine effectiveness against COVID-19-related hospitalisation, ICU admission, and death was 86·3% (83·7-88·5), 92·2% (88·7-94·6), and 86·7% (80·5-91·0) for a homologous CoronaVac booster, 96·1% (95·3-96·9), 96·2% (94·6-97·3), and 96·8% (93·9-98·3) for a BNT162b2 booster, and 97·7% (97·3-98·0), 98·9% (98·5-99·2), and 98·1% (97·3-98·6) for an AZD1222 booster. INTERPRETATION: Our results suggest that a homologous or heterologous booster dose for individuals with a complete primary vaccination schedule with CoronaVac provides a high level of protection against COVID-19, including severe disease and death. Heterologous boosters showed higher vaccine effectiveness than a homologous booster for all outcomes, providing additional support for a mix-and-match approach. FUNDING: Agencia Nacional de Investigación y Desarrollo through the Fondo Nacional de Desarrollo Científico y Tecnológico, Millennium Science Initiative Program, and Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias.
引用
- Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022. PMID: 35472300. doi:10.1016/S2214-109X(22)00112-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。